This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|April 22, 2014
PEARLITOL® mannitol
Since the 1970's, Roquette has been continuously working on improving the remarkable intrinsic properties by providing mannitol with DC properties, self disintegration, low endotoxin level, leading to the creation of the largest mannitol range for the pharmaceutical industry.
Advertisement
Continuous commitment to Mannitol development to Support the growth of the Pharmaceutical Market Segments
Mannitol has a share of the most desirable qualities that formulators seek in mineral, sugar or even polymeric excipients: notably a characteristic low chemical reactivity, an extraordinarily low level of hygroscopicity making it one of the "driest" products for moisture sensitive formulation, coupled with a pleasant taste and mouthfeel.
Since the 1970’s, Roquette has been continuously working on improving the remarkable intrinsic properties by providing mannitol with DC properties, self disintegration, low endotoxin level, leading to the creation of the largest mannitol range for the pharmaceutical industry: PEARLITOL® C, SD, DC, FLASH and PF.
Company name: ROQUETTE
Website:
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement